Oxford and the savannah: Can the Hippo provide an explanation for Peto's paradox?

Clinical Cancer Research

Volumn 20, Issue 3, 2014, Pages 557-564

  Kelleher, Fergal C ^a   O'Sullivan, Hazel ^b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b WHANGAREI HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; BODY SIZE; COMPUTER SIMULATION; GENES, TUMOR SUPPRESSOR; HUMANS; MODELS, THEORETICAL; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 84893449856     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2010     Document Type: Review

References (52)

1. Grusche FA, Richardson HE, Harvey KF. Upstream regulation of the hippo size control pathway. Curr Biol 2010;20:R574-82.
2. Halder G, Johnson RL. Hippo signaling: growth control and beyond. Development 2011;138:9-22.
3. Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010;19:491-505.
4. Zhao B, Li L, Lei Q, Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev 2010;24:862-74.
5. Badouel C, McNeill H. SnapShot: The hippo signaling pathway. Cell 2011;145:484-484.e1.
6. Leroi AM, Koufopanou V, Burt A. Cancer selection. Nat Rev Cancer 2003;3:226-31.
7. Nagy JD, Victor EM, Cropper JH. Why don't all whales have cancer? A novel hypothesis resolving Peto's paradox. Integr Comp Biol 2007; 47:317-28.
8. Roche B, Sprouffske K, Hbid H, Misse D, Thomas F. Peto's paradox revisited: theoretical evolutionary dynamics of cancer in wild populations. Evol Appl 2013;6:109-16.
9. Roche B, Hochberg ME, Caulin AF, Maley CC, Gatenby RA, Misse D, et al. Natural resistance to cancers: a Darwinian hypothesis to explain Peto's paradox. BMC Cancer 2012;12:387.
10. Cha J, Sun X, Bartos A, Fenelon J, Lefevre P, Daikoku T, et al. A new role for muscle segment homeobox genes in mammalian embryonic diapause. Open Biol 2013;3:130035.
11. Chan EH, Nousiainen M, Chalamalasetty RB, Schafer A, Nigg EA, Sillje HH. The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene 2005;24:2076-86.
12. Hergovich A, Schmitz D, Hemmings BA. The human tumour suppressor LATS1 is activated by human MOB1 at the membrane. Biochem Biophys Res Commun 2006;345:50-8.
13. Callus BA, Verhagen AM, Vaux DL. Association of mammalian sterile twenty kinases, Mst1 and Mst2, with hSalvador via C-terminal coiledcoil domains, leads to its stabilization and phosphorylation. FEBS J 2006;273:4264-76.
14. Abdollahpour H, Appaswamy G, Kotlarz D, Diestelhorst J, Beier R, Schaffer AA, et al. The phenotype of human STK4 deficiency. Blood 2012;119:3450-7.
15. Xin M, Kim Y, Sutherland LB, Qi X, McAnally J, Schwartz RJ, et al. Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size. Sci Signal 2011;4:ra70.
16. Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer 2013;13:246-57.
17. Sotelo-Avila C, Gonzalez-Crussi F, Fowler JW. Complete and incomplete forms of Beckwith-Wiedemann syndrome: their oncogenic potential. J Pediatr 1980;96:47-50.
18. Oudhoff MJ, Freeman SA, Couzens AL, Antignano F, Kuznetsova E, Min PH, et al. Control of the hippo pathway by Set7-dependent methylation of Yap. Dev Cell 2013;26:188-94.
19. Bartels H. Metabolic rate of mammals equals the 0.75 power of their body weight. Exp Biol Med 1982;7:1-11.
20. Klieber M. Body size and metabolism. Hilgardia 1932;6:315-53.
21. Kolokotrones T, Van S, Deeds EJ, Fontana W. Curvature in metabolic scaling. Nature 2010;464:753-6.
22. Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol 2011;12:83-91.
23. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008;7:11-20.
24. Cantor JR, Sabatini DM. Cancer cell metabolism: one hallmark, many faces. Cancer Discov 2012;2:881-98.
25. Linehan WM, Rouault TA. Molecular pathways: Fumarate hydratasedeficient kidney cancer-targeting the Warburg effect in cancer. Clin Cancer Res 2013;19:3345-52.
26. Groves AM, Win T, Haim SB, Ell PJ. Non-[18F]FDG PET in clinical oncology. Lancet Oncol 2007;8:822-30.
27. Effert PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 1996; 155:994-8.
28. Ohsawa S, Sato Y, Enomoto M, Nakamura M, Betsumiya A, Igaki T. Mitochondrial defect drives non-autonomous tumour progression through Hippo signalling in Drosophila. Nature 2012;490:547-51.
29. Csibi A, Blenis J. Hippo-YAP and mTOR pathways collaborate to regulate organ size. Nat Cell Biol 2012;14:1244-5.
30. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009;10:307-18.
31. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93.
32. Kohn AD, Summers SA, Birnbaum MJ, Roth RA. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem 1996;271:31372-8.
33. Deprez J, Vertommen D, Alessi DR, Hue L, Rider MH. Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades. J Biol Chem 1997;272:17269-75.
34. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 2001;15:1406-18.
35. Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 2003;23:7315-28.
36. Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, et al. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 2012;30:2919-28.
37. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12:21-35.
38. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003;115:577-90.
39. Gwinn DM, Shackelford DB, Egan DF, MihaylovaMM, Mery A, Vasquez DS, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008;30:214-26.
40. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, et al. The tumor suppressor LKB1 kinase directly activates AMPactivated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 2004;101:3329-35.
41. Pal A, Barber TM, Van de Bunt M, Rudge SA, Zhang Q, Lachlan KL, et al. PTEN mutations as a cause of constitutive insulin sensitivity and obesity. N Engl J Med 2012;367:1002-11.
42. Tumaneng K, Schlegelmilch K, Russell RC, Yimlamai D, Basnet H, Mahadevan N, et al. YAP mediates crosstalk between the Hippo and PI (3)K-TOR pathways by suppressing PTEN via miR-29. Nat Cell Biol 2012;14:1322-9.
43. Zhou L, Wang L, Lu L, Jiang P, Sun H, Wang H. Inhibition of miR-29 by TGF-beta-Smad3 signaling through dual mechanisms promotes transdifferentiation of mouse myoblasts into myofibroblasts. PloS ONE 2012;7:e33766.
44. Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012;150:780-91.
45. Hulmi JJ, Oliveira BM, Silvennoinen M, Hoogaars WM, Ma H, Pierre P, et al. Muscle protein synthesis, mTORC1/MAPK/Hippo signaling, and capillary density are altered by blocking ofmyostatin and activins.AmJ Physiol Endocrinol Metab 2013;304:E41-50.
46. Shackelford DB, Shaw RJ. The LKB1-AMPKpathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009;9:563-75.
47. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998;391:184-7.
48. Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM, et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 2002;62:3659-62.
49. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 2013;31:3069-75.
50. Shaw RJ. LKB1: cancer, polarity, metabolism, and now fertility. Biochem J 2008;416:e1-3.
51. Towler MC, Fogarty S, Hawley SA, Pan DA, Martin DM, Morrice NA, et al. A novel short splice variant of the tumour suppressor LKB1 is required for spermiogenesis. Biochem J 2008;416:1-14.
52. Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012; 485:661-5.